Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 4, 2012

Boehringer Ingelheim’s Afatinib Extends PFS in EGFR Mutation-Positive NSCLC

  • Boehringer Ingelheim reported positive data from a Phase III trial evaluating afatinib as first-line therapy in patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). The open-label LUX-Lung 3 study is comparing once-daily oral afatinib with pemetrexed/cisplatin chemotherapy in 345 patients with stage IIIb or IV disease. The results showed that in the overall patient population afatinib therapy was associated with a PFS of 11.1 months, compared with 6.9 months for patients treated using chemotherapy.

    About 90% of patients in the study harbor the most common Del19 or L858R EGFR mutations. In this subset of patients afatinib therapy was associated with a median PFS of 13.6 months, compared with 6.9 months for patients in the chemotherapy arm.

    Afatinib is an irreversible ERbB family blocker that targets EGFR (ErbB1), Her2 (ErbB2), and ErbB4. The drug is currently undergoing Phase III development as a treatment for NSCLC, head and neck cancer, and breast cancer. The LUX-Lung program includes eight studies evaluating afatinib in the treatment of advanced NSCLC. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »